Background A retrospective analysis of clinical data were conducted reviewing patients who
were given erlotinib at Peking Union Medical College (PUMC) Hospital from May 2005 to …

chemotherapy in terms of PFS, main endpoint of the trial, with 9.7 versus 5.2 months,
respectively (HR 0.37, 95% CI 0.25-0.54). ORRs were 58% and 15%, respectively. OS data …

e19077 Background: There is laboratory evidence that digoxin sensitizes cancer cells to the
induction of apoptosis by chemotherapy. Inhibition of the Na/K-ATPase enzyme by ouabain …

Erlotinib is a potent reversible HER1/epidermal growth factor receptor tyrosine kinase
inhibitor with single-agent activity in patients with non-small cell lung cancer. The aim of this …

Purpose: The purpose of the present trial was to investigate whether clinical benefit can be
obtained by concurrent administration of erlotinib with gemcitabine as first-line treatment in …

Background. EGFR and Src are frequently activated in non-small cell lung cancer (NSCLC).
In preclinical models, combining EGFR and Src inhibition has additive synergistic effects …

Background: A phase III trial was conducted to compare the safety and efficacy of erlotinib
with that of gefitinib in advanced non-small cell lung cancer harbouring epidermal growth …

Epidermal growth factor receptor (EGFR) is a transmembrane receptor with a cytoplasmic
tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung …

Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …

Importance of the field: Erlotinib, a potent inhibitor of EGFR activity, is approved as a
monotherapy for the treatment of advanced NSCLC and in combination with gemcitabine for …